RHEPaiR

• Research type

  Research Study

• Full title

  Individualized dosimetry for holmium-166- radioembolization in patients with unresectable hepatocellular carcinoma; a multi-center, interventional, non-randomized, non-comparative, open label, early phase II study

• IRAS ID

  326861

• Contact name

  Rohini Sharma

• Contact email

  r.sharma@imperial.ac.uk

• Sponsor organisation

  Imperial College London

• Eudract number

  2022-002957-25

• Duration of Study in the UK

  2 years, 11 months, 30 days

• Research summary

  Patients who meet the study eligibility criteria and cannot undergo surgery for their hepatocellular carcinoma (liver cancer) will be offered the option of taking part in this trial and receive selective internal radiation therapy with Holmium-166, which is a radioactive isotope known to give off a high dose of radiation in a relatively short amount of time.

• REC name

  East Midlands - Nottingham 1 Research Ethics Committee

• REC reference

  23/EM/0239

• Date of REC Opinion

  21 Dec 2023

• REC opinion

  Further Information Favourable Opinion